In this piece, we bring a summary of the latest clinical data from Editas Medicine's ongoing RUBY trial for EDIT-301 in severe sickle cell disease, as...

Last week, Editas Medicine announced successful engraftment of the first patient dosed with the CRISPR-based therapeutic candidate EDIT-301 for the...

This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

In this roundup, we look at what's going on in the CRISPR Medicine field for Leber congenital amaurosis, an inherited group of rare retinal diseases...

This week's clinical update features news from Editas Medicine, which recently announced that the U.S. Food and Drug Administration (FDA) has granted...

Editas Medicine announced earlier this week that it had dosed the first child in the BRILLIANCE clinical trial of EDIT-101 for Leber congenital...

In this week's clinical trial update, we summarise the ongoing in vivo CRISPR clinical trials for three distinct rare genetic diseases: hereditary...

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...